{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:46:02Z","timestamp":1772793962711,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"DOI":"10.1186\/s12866-025-03746-6","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T08:08:49Z","timestamp":1737101329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of extracts from used Xpert MTB\/RIF cartridges for detection of resistance to second-line anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis in Ethiopia"],"prefix":"10.1186","volume":"25","author":[{"given":"Tilahun","family":"Ketema","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mulualem","family":"Tadesse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zegeye","family":"Bonsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Getu","family":"Balay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wakjira","family":"Kebede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mekidim","family":"Mekonnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemeda","family":"Abebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"3746_CR1","unstructured":"World Health Organization. World health statistics 2022: monitoring health for the SDGs, sustainable development goals. World Health Organization; 2022."},{"key":"3746_CR2","unstructured":"World Health Organization. Global tuberculosis report 2023. World Health Organization; 2023."},{"key":"3746_CR3","unstructured":"World Health Organization. Global tuberculosis Report 2022. World Health Organization; 2023."},{"issue":"10","key":"3746_CR4","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3390\/tropicalmed7100300","volume":"7","author":"MA Reta","year":"2022","unstructured":"Reta MA, Tamene BA, Abate BB, Mensah E, Maningi NE, Fourie PB. Mycobacterium tuberculosis Drug Resistance in Ethiopia: an updated systematic review and Meta-analysis. Trop Med Infect Dis. 2022;7(10):300.","journal-title":"Trop Med Infect Dis"},{"key":"3746_CR5","unstructured":"World Health Organization. Fact sheets on tuberculosis. World Health Organization; 2023."},{"key":"3746_CR6","unstructured":"World Health Organization. Questions and answer on tuberculosis: extensively drug-resistant tuberculosis. XDR-TB).World Health Organization; 2024."},{"key":"3746_CR7","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.2147\/IDR.S381643","volume":"15","author":"L Nandlal","year":"2022","unstructured":"Nandlal L, Perumal R, Naidoo K. Rapid Molecular assays for the diagnosis of drug-resistant tuberculosis. Infect Drug Resist. 2022;15:4971\u201384.","journal-title":"Infect Drug Resist"},{"issue":"1","key":"3746_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/pathogens13010027","volume":"13","author":"K Naidoo","year":"2023","unstructured":"Naidoo K, Perumal R, Ngema SL, Shunmugam L, Somboro AM. Rapid diagnosis of Drug-Resistant Tuberculosis-opportunities and challenges. Pathogens. 2023;13(1):27.","journal-title":"Pathogens"},{"key":"3746_CR9","doi-asserted-by":"publisher","first-page":"100410","DOI":"10.1016\/j.jctube.2023.100410","volume":"34","author":"Z Bonsa","year":"2023","unstructured":"Bonsa Z, Tadesse M, Balay G, Kebede W, Abebe G. Discordance between genotypic and phenotypic methods for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis and the correlation with patient treatment outcomes. J Clin Tuberc Other Mycobact Dis. 2023;34:100410.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"4","key":"3746_CR10","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.22207\/JPAM.17.4.56","volume":"17","author":"MM Tawfick","year":"2023","unstructured":"Tawfick MM, Badawy MSEM, Taleb MH, Menofy EL. Tuberculosis diagnosis and detection of Drug Resistance: a comprehensive updated review. J Pure Appl Microbiol. 2023;17(4):1978\u20132009.","journal-title":"J Pure Appl Microbiol"},{"issue":"4","key":"3746_CR11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.4103\/ijmy.ijmy_135_18","volume":"7","author":"PM Mbelele","year":"2018","unstructured":"Mbelele PM, Mohamed SY, Sauli E, Mpolya EA, Mfinanga SG, Addo KK, et al. Meta-narrative review of molecular methods for diagnosis and monitoring of multidrug-resistant tuberculosis treatment in adults. Int J Mycobacteriol. 2018;7(4):299\u2013309.","journal-title":"Int J Mycobacteriol"},{"issue":"2","key":"3746_CR12","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3390\/clinpract14020030","volume":"14","author":"N Zaporojan","year":"2024","unstructured":"Zaporojan N, Negrean RA, Hodi\u0219an R, Zaporojan C, Csep A, Zaha DC. Evolution of Laboratory diagnosis of tuberculosis. Clin Pract. 2024;14(2):388\u2013416.","journal-title":"Clin Pract"},{"issue":"3","key":"3746_CR13","first-page":"299","volume":"12","author":"R Radhakrishnan","year":"2023","unstructured":"Radhakrishnan R, Prabuseenivasan S, Hannah S, Vaishanavee V, Senthildevi V, Kannadhasan T, et al. Genotype MTBDRsl version 2 and phenotypic drug resistance detection of Mycobacterium tuberculosis for fluoroquinolones and aminoglycosides. Int J Mycobacteriol. 2023;12(3):299\u2013304.","journal-title":"Int J Mycobacteriol"},{"issue":"Suppl 1","key":"3746_CR14","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.4103\/2212-5531.307117","volume":"10","author":"J Kardan-Yamchi","year":"2021","unstructured":"Kardan-Yamchi J, Kazemian H, Abtahi H, Amini S, Feizabadi MM. Assessment of line probe assay for rapid detection of extensively drug-resistant Mycobacterium tuberculosis isolates. Int J Mycobacteriol. 2021;10(Suppl 1):S65.","journal-title":"Int J Mycobacteriol"},{"issue":"2","key":"3746_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.4103\/ijmy.ijmy_86_23","volume":"12","author":"S Kanade","year":"2023","unstructured":"Kanade S, Mohammed Z, Kulkarni A, Nataraj G. Comparison of Xpert MTB\/RIF Assay, line probe assay, and culture in diagnosis of pulmonary tuberculosis on bronchoscopic specimen. Int J Mycobacteriol. 2023;12(2):151\u20136.","journal-title":"Int J Mycobacteriol"},{"issue":"4","key":"3746_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.4103\/ijmy.ijmy_138_19","volume":"8","author":"PM Christopher","year":"2019","unstructured":"Christopher PM, Cucunawangsih, Widysanto A. GeneXpert Mycobacterium tuberculosis\/rifampicin assay for molecular epidemiology of rifampicin-resistant Mycobacterium tuberculosis in an Urban setting of Banten province, Indonesia. Int J Mycobacteriol. 2019;8(4):351\u20138.","journal-title":"Int J Mycobacteriol"},{"issue":"2","key":"3746_CR17","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4103\/ijmy.ijmy_83_19","volume":"8","author":"M Habous","year":"2019","unstructured":"Habous M, Elimam E, Kumar MA, L Deesi R. Evaluation of GeneXpert Mycobacterium tuberculosis\/Rifampin for the detection of Mycobacterium tuberculosis complex and rifampicin resistance in nonrespiratory clinical specimens. Int J Mycobacteriol. 2019;8(2):132\u20137.","journal-title":"Int J Mycobacteriol"},{"issue":"6","key":"3746_CR18","first-page":"CD009593","volume":"6","author":"DJ Horne","year":"2019","unstructured":"Horne DJ, Kohli M, Zifodya JS, Schiller I, Dendukuri N, Tollefson D, et al. Xpert MTB\/RIF and Xpert MTB\/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2019;6(6):CD009593.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"3746_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.5588\/ijtld.19.0298","volume":"24","author":"JS Ngabonziza","year":"2020","unstructured":"Ngabonziza JS, Habimana YM, Decroo T, Migambi P, Dushime A, Mazarati JB, et al. Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in Rwanda. Int J Tuberc Lung Dis. 2020;24(3):329\u201339.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"3746_CR20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1473-3099(21)00452-7","volume":"22","author":"A Penn-Nicholson","year":"2022","unstructured":"Penn-Nicholson A, Georghiou SB, Ciobanu N, Kazi M, Bhalla M, David A, et al. Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB\/XDR assay: a cross-sectional multicentre diagnostic accuracy study. Lancet Infect Dis. 2022;22(2):242\u20139.","journal-title":"Lancet Infect Dis"},{"key":"3746_CR21","unstructured":"Cepheid, Xpert. MTB-XDR English package insert. Cepheid; 2021."},{"key":"3746_CR22","unstructured":"World Health Organization. WHO operational handbook on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection, 2021 update. World Health Organization; 2021."},{"issue":"1","key":"3746_CR23","doi-asserted-by":"publisher","first-page":"14854","DOI":"10.1038\/s41598-017-14385-x","volume":"7","author":"R Venter","year":"2017","unstructured":"Venter R, Derendinger B, de Vos M, Pillay S, Dolby T, Simpson J, et al. Mycobacterial genomic DNA from used Xpert MTB\/RIF cartridges can be utilised for accurate second-line genotypic drug susceptibility testing and spoligotyping. Sci Rep. 2017;7(1):14854.","journal-title":"Sci Rep"},{"issue":"1","key":"3746_CR24","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1038\/s41598-020-59164-3","volume":"10","author":"R Venter","year":"2020","unstructured":"Venter R, Minnies S, Derendinger B, Tshivhula H, de Vos M, Dolby T, et al. Extract from used Xpert MTB\/RIF Ultra cartridges is useful for accurate second-line drug-resistant tuberculosis diagnosis with minimal rpob-amplicon cross-contamination risk. Sci Rep. 2020;10(1):2633.","journal-title":"Sci Rep"},{"key":"3746_CR25","unstructured":"Hain Lifescience GmbH. GenoType MTBDRsl VER 2.0 instructions for use. Hain Lifescience GmbH; 2017."},{"key":"3746_CR26","doi-asserted-by":"publisher","first-page":"17850","DOI":"10.1038\/srep17850","volume":"6","author":"M Tomasicchio","year":"2016","unstructured":"Tomasicchio M, Theron G, Pietersen E, Streicher E, Stanley-Josephs D, van Helden P, et al. The diagnostic accuracy of the MTBDRplus and MTBDRsl assays for drug-resistant TB detection when performed on sputum and culture isolates. Sci Rep. 2016;6:17850.","journal-title":"Sci Rep"},{"key":"3746_CR27","unstructured":"World Health Organization. Line probe assays for detection of drug-resistant tuberculosis: interpretation and reporting manual for laboratory staff and clinicians. World Health Organization; 2022."},{"issue":"10","key":"3746_CR28","doi-asserted-by":"publisher","first-page":"839","DOI":"10.5588\/ijtld.21.0212","volume":"25","author":"M Ejo","year":"2021","unstructured":"Ejo M, Van Deun A, Nunn A, Meredith S, Ahmed S, Dalai D, et al. Effectiveness of GenoType MTBDRsl in excluding TB drug resistance in a clinical trial. Int J Tuberc Lung Dis. 2021;25(10):839\u201345.","journal-title":"Int J Tuberc Lung Dis"},{"key":"3746_CR29","unstructured":"World Health Organization. The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs. Policy guidance. World Health Organization; 2016."}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-03746-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-025-03746-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-025-03746-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T08:08:59Z","timestamp":1737101339000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmicrobiol.biomedcentral.com\/articles\/10.1186\/s12866-025-03746-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3746"],"URL":"https:\/\/doi.org\/10.1186\/s12866-025-03746-6","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"assertion":[{"value":"8 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was carried out in compliance with the Declaration of Helsinki. The Institutional Review Board (IRB) at the Institute of Health, Jimma University, Ethiopia, approved the study protocol (Reference No. IHRPG\/45\/2020). Informed consent was obtained from all patients for the use of their data for research purposes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}